Market Overview

Cowen Raises Sage Value On New Phase 2 Trial Success

Cowen Raises Sage Value On New Phase 2 Trial Success
Benzinga's Top Upgrades, Downgrades For August 6, 2018
Canaccord Previews Biotech Catalysts In The Second Half: Neurological Drugs In Focus
Biotech Stocks: Niche Operators Scientifically, Competing Directly As Investments (Seeking Alpha)

SAGE Therapeutics Inc (NASDAQ: SAGE) released Thursday positive top-line data from its Phase 2 study of SAGE-217 in major depressive disorder (MDD).

The news immediately propelled Sage's stock, rocketing it past previous highs to $169.58. Cowen thinks there’s still upside.

The Rating

Cowen analyst Ritu Baral maintained an Outperform rating on Sage and raised his price target from $135 to $202.

The Thesis

The treatment demonstrated statistical significance within 12 hours, sustained efficacy for four weeks, and met primary endpoints with “impressive, rapid, durable effectiveness.”

It also showed a positive safety profile with broad tolerance and common adverse effects. Previous concerns about elevated sedation levels were largely mitigated by night-time dosing and an altered capsule formulation.

“With a unique mechanism, superior efficacy, faster onset and good tolerability (as well potential benefits on sleep) compared to SSRIs, '217 can potentially become the first-line treatment for MDD with a potential for premium pricing to even branded SSRIs,” Baral wrote, noting that the program is ready for Phase 3.

Baral expects regulatory approval particularly considering the indication’s fast-track designation and Sage’s plan to pursue breakthrough designation. She anticipates peak MDD sales of $1.5 billion with potential additional sales for Parkinson’s and Essential tremor.

Price Action

At time of publication, Sage was trading up 76.5 percent at a rate of $162.22.

Related Links:

Michael Phelps Opens Up About Struggles With ADHD, Depression: I Was Constantly Bouncing Off The Wall As A Kid

Phelps Talks Mental Health Awareness, Medibio's Algorithmic Diagnosis

Latest Ratings for SAGE

Aug 2018PiperJaffrayInitiates Coverage OnOverweight
Jul 2018Morgan StanleyMaintainsOverweightOverweight
Jun 2018Canaccord GenuityMaintainsBuyBuy

View More Analyst Ratings for SAGE
View the Latest Analyst Ratings

Posted-In: Cowen major depressive disorder Ritu BaralAnalyst Color Price Target Top Stories Analyst Ratings Best of Benzinga


Related Articles (SAGE)

View Comments and Join the Discussion!

Amid Shift To Electric Vehicles, Analyst Looks For BorgWarner To Benefit

A Detailed Look Inside Leon Cooperman's Stock Portfolio